UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 62

Sortiert nach

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

The lancet oncology, 2022-01, Vol.23 (1), p.91-103

2022

Link zum Volltext

Verfügbarkeit prüfen

Age barriers in allogeneic hematopoietic cell transplantation: Raising the silver curtain

American journal of hematology, 2024-05, Vol.99 (5), p.922-937

2024

Link zum Volltext

Verfügbarkeit prüfen

6‐Thioguanine: A Drug With Unrealized Potential for Cancer Therapy

The oncologist (Dayton, Ohio), 2014-07, Vol.19 (7), p.760-765

2014

Link zum Volltext

Verfügbarkeit prüfen

Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission

Blood, 2022-03, Vol.139 (9), p.1330-1339

2022

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older

Cancer, 2021-11, Vol.127 (22), p.4233-4239

2021

Link zum Volltext

Verfügbarkeit prüfen

Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide–Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma

Biology of blood and marrow transplantation, 2019-09, Vol.25 (9), p.1859-1868

2019

Link zum Volltext

Verfügbarkeit prüfen

The acceleration of CAR‐T therapy in non‐Hodgkin lymphoma

Hematological oncology, 2019-08, Vol.37 (3), p.233-239

2019

Link zum Volltext

Verfügbarkeit prüfen

Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients

Blood advances, 2023-01, Vol.7 (1), p.32-39

2023

Link zum Volltext

Verfügbarkeit prüfen

Post-transplantation cyclophosphamide is associated with increased bacterial infections

Bone marrow transplantation (Basingstoke), 2024-01, Vol.59 (1), p.76-84

2024

Link zum Volltext

Verfügbarkeit prüfen

Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant

JAMA oncology, 2021-07, Vol.7 (7), p.993

2021

Link zum Volltext

Verfügbarkeit prüfen

ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Relapsed Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T-Cell Therapy

Transplantation and cellular therapy, 2024-04

2024

Link zum Volltext

Verfügbarkeit prüfen

Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis

Blood advances, 2023-06, Vol.7 (12), p.2746-2757

2023

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of Consolidation Therapy with Ipilimumab Plus Nivolumab after Autologous Stem Cell Transplantation

Transplantation and cellular therapy, 2021-05, Vol.27 (5), p.391-403

2021

Link zum Volltext

Verfügbarkeit prüfen

Sustained Hematopoietic Engraftment Potential after Prolonged Storage of Cryopreserved Hematopoietic Stem Cells Used in Salvage Autologous Stem Cell Transplantation

Transplantation and cellular therapy, 2022-06, Vol.28 (6), p.306.e1-306.e7

2022

Link zum Volltext

Verfügbarkeit prüfen

Subsequent Cancers in Patients Affected with Moderate or Severe Chronic Graft-versus-Host Disease

Transplantation and cellular therapy, 2021-11, Vol.27 (11), p.937.e1-937.e7

2021

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma

Transplantation and cellular therapy, 2022-08, Vol.28 (8), p.487.e1-487.e7

2022

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research

Transplantation and cellular therapy, 2022-04, Vol.28 (4), p.187.e1-187.e10

2022

Link zum Volltext

Verfügbarkeit prüfen

American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma

Transplantation and cellular therapy, 2021-09, Vol.27 (9), p.720-728

2021

Link zum Volltext

Verfügbarkeit prüfen

Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy

Transplantation and cellular therapy, 2021-12, Vol.27 (12), p.993.e1-993.e8

2021

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of Upfront Autologous Hematopoietic Cell Transplantation in Multiple Myeloma patients 75 years and older

Cancer, 2021-08, Vol.127 (22), p.4233-4239

2021

Link zum Volltext

Verfügbarkeit prüfen

Adhering to Recommended Lifestyle Changes and Medications 9 Months to 3 Years after Hematopoietic Stem Cell Transplant: Self-Reported Adherence and the Practical, Psychological, and Social Correlates of Adherence

Blood, 2018-11, Vol.132 (Supplement 1), p.4799-4799

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 62

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(60)

Publikationsform

Artikel
(59)
Buchkapitel
(3)

Sprache

Englisch
(62)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(23)
Science & Technology
(23)
Humans
(21)
Hematology
(18)
Transplantation
(13)
Immunology
(10)
Oncology
(9)
Aged
(8)
Hematopoietic Stem Cell Transplantation
(8)
Lymphoma
(8)
Middle Aged
(8)
Hematopoietic Stem Cell Transplantation - Adverse Effects
(7)
Male
(6)
Transplants & Implants
(6)
Adult
(5)
Female
(5)
Hematopoietic Stem Cells
(5)
Medicin Och Hälsovetenskap
(5)
Multiple Myeloma
(5)
Recurrence
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

Age barriers in allogeneic hematopoietic cell transplantation: Raising the silver curtain

6‐Thioguanine: A Drug With Unrealized Potential for Cancer Therapy

Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission

Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older

Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide–Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

The acceleration of CAR‐T therapy in non‐Hodgkin lymphoma

Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma

Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients

Post-transplantation cyclophosphamide is associated with increased bacterial infections

ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma

Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant

ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Relapsed Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T-Cell Therapy

Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis

Safety and Efficacy of Consolidation Therapy with Ipilimumab Plus Nivolumab after Autologous Stem Cell Transplantation

Sustained Hematopoietic Engraftment Potential after Prolonged Storage of Cryopreserved Hematopoietic Stem Cells Used in Salvage Autologous Stem Cell Transplantation

Subsequent Cancers in Patients Affected with Moderate or Severe Chronic Graft-versus-Host Disease

Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma

Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research

American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma

Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy

Outcomes of Upfront Autologous Hematopoietic Cell Transplantation in Multiple Myeloma patients 75 years and older

Adhering to Recommended Lifestyle Changes and Medications 9 Months to 3 Years after Hematopoietic Stem Cell Transplant: Self-Reported Adherence and the Practical, Psychological, and Social Correlates of Adherence

3-Year Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Suchergebnisse filtern